Bicara Therapeutics Inc

NEW
NAS:BCAX (USA)  
$ 13.54 +0.14 (+1.04%) 10:00 AM EST
At Loss
P/B:
1.45
Market Cap:
$ 736.79M
Enterprise V:
$ 222.73M
Volume:
15.36K
Avg Vol (2M):
481.94K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
15.36K
At Loss
Avg Vol (2M):
481.94K

Business Description

Bicara Therapeutics Inc
NAICS : 541715 SIC : 2833
ISIN : US0554771032
Description
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Name Current Vs Industry Vs History
Cash-To-Debt 1170.24
Equity-to-Asset 0.97
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 53.4
9-Day RSI 50.58
14-Day RSI 49.87
3-1 Month Momentum % -32.35
6-1 Month Momentum % -51.42

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 36.01
Quick Ratio 36.01
Cash Ratio 35.96

Dividend & Buy Back

Name Current Vs Industry Vs History

Financials (Next Earnings Date:2025-03-28 Est.)

BCAX's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BCAX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Bicara Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.836
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % -
14-Day RSI 49.87
14-Day ATR ($) 1.2867
20-Day SMA ($) 13.6745
12-1 Month Momentum % -
52-Week Range ($) 11.1 - 28.09
Shares Outstanding (Mil) 54.42

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Bicara Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Bicara Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Bicara Therapeutics Inc Frequently Asked Questions

What is Bicara Therapeutics Inc(BCAX)'s stock price today?
The current price of BCAX is $13.54. The 52 week high of BCAX is $28.09 and 52 week low is $11.10.
When is next earnings date of Bicara Therapeutics Inc(BCAX)?
The next earnings date of Bicara Therapeutics Inc(BCAX) is 2025-03-28 Est..
Does Bicara Therapeutics Inc(BCAX) pay dividends? If so, how much?
Bicara Therapeutics Inc(BCAX) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1